About Avidity Biosciences, a Novartis Company
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs – that will treat serious, genetic neuromuscular diseases. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. On February 27, 2026, Avidity Biosciences became an indirect, wholly owned subsidiary of Novartis AG. The acquisition of Avidity was originally announced on October 26, 2025.
News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
June 9, 2025-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and...
June 9, 2025-- Planning accelerated approval BLA submission in H2 2026, following topline data from FORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD™ study of...
-
May 21, 2025
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
-
May 8, 2025
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further...
-
May 6, 2025
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...